Diabetes mellitus has been associated with increased risk for the development of many types of cancer. Metformin, an oral medication and first-line treatment for type 2 diabetes mellitus, has been suggested to reduce cancer risk and mortality in various types of cancer. This study focuses on assessing metformin association with lung cancer as reported in the literature. Recent studies and reviews investigating metformin effects on lung cancer incidence and patient survival are critically and systematically discussed.
aDepartment of Clinical Pharmacy and Pharmacy Practice, Dubai Pharmacy College
bDepartment of Biochemistry, Dubai Medical College, Dubai, United Arab Emirates
Correspondence to Juliana F. Roos, PhD, DipClinPharm, DipMgt, BPharm, Department of Clinical Pharmacy and Pharmacy Practice, Dubai Pharmacy College, PO Box 19099, Al Muhaisanah 1, Al Mizhar, Dubai, United Arab Emirates Tel: +971 4212 0319; fax: +971 4264 6740; e-mail: Dr.Juliana@dpc.edu
Received November 22, 2017
Accepted January 22, 2018